Gene editing solutions for companion animal health
Pilot trials enrolling Q2 2024
University of Minnesota
Ohio State University
University of Missouri
North Carolina State University
LEAH Labs will be enrolling pet patients with B cell lymphoma in a fully funded pilot efficacy trial
We are developing CAR-T cell therapy, an FDA-approved, often curative treatment for humans with cancer. LEAH Labs is working to bring this breakthrough therapy to our furry family members with similar cancers.
CAR-T cell therapy involves genetically reprogramming T immune cells so they can seek out cancer, recognize it like a lock and key, and destroy it.
LEAH Labs’ trials are available to licensed veterinarians and their patients under 9 CFR 103.3.
Safety and efficacy of our experimental products have not been established with or approved by USDA-CVB.
With funding from:
Investors:
Y Combinator, AgStartup Engine, FIN Capital,
Southeast Minnesota Capital,
Wefunder, various angel investors
Grants:
NSF SBIR, NIH SBIR, LaunchMN,
Regenerative Medicine Minnesota
